Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates

CONCLUSION: The addition of anifrolumab to SoC is a cost-effective option versus belimumab for the treatment of adult patients with active, autoantibody-positive SLE, despite being allocated to SoC. Cost-effectiveness was demonstrated by a reduction in complications and organ damage, which reflected costs and outcomes.PMID:38468481 | DOI:10.1080/13696998.2024.2320603
Source: Journal of Medical Economics - Category: Health Management Authors: Source Type: research